(845)-471-1807 info@tmshudsonvalley.com

NeuroStar Efficacy and Safety

Clinical trials have demonstrated the effectiveness of NeuroStar® TMS Therapy in treating patients who have not benefited from prior antidepressant medication. NeuroStar TMS Therapy was studied in adult patients suffering from Major Depressive Disorder, all of whom had not received satisfactory improvement with previous treatments.

Please note, TMS Therapy may not be safe for patients with implanted or non-removeable metallic devices in or around the head, pacemakers, implantable cardioverter defibrillators (ICDs) or vagus nerve simulators (VNS).

An Effective and Durable Option for Treating Major Depressive Disorder

concerned-patient-tms

Patients are 4x more likely to achieve remission with TMS

At the end of their treatments, patients who had received NeuroStar TMS Therapy were four times more likely to achieve remission compared to patients receiving a sham treatment. 1 in 2 patients experienced significant improvement in their depression symptoms and 1 in 3 experienced complete remission. Patients treated with the NeuroStar TMS System also experienced significant improvement in anxiety and physical symptoms (such as appetite changes, aches and pains, and lack of energy) associated with depression.

Durability of TMS Treatments

NeuroStar TMS is the only TMS system with the durability of its effects established over 12 months.

In a trial with physician directed standard of care, meaning Neurostar TMS Therapy could be used in conjunction with antidepressants as needed, patients who had received treatment then reported their symptom levels at 3, 6, 9 and 12 months to determine the durability of their treatments. By the end of the 12-month period, 2 out of 3 patients who had either responded or completely remitted after TMS treatment remained at the symptom levels they reported at the end of the treatment phase.

After the end of the treatment period, only 1 in 3 patients needed to come back for maintenance TMS sessions, or ‘reintroduction’ during this 12-month period.

Transcranial Magnetic Stimulation

TMS Therapy Safety Tested Through Clinical Trials

Clinical trials have proven the safety of NeuroStar TMS Therapy in the treatment of patients with major depressive disorder and who have had an inadequate response to prior antidepressant medication.

Over 10,000 treatments were perform across NeuroStar clinical trials demonstrating its safety. NeuroStar TMS Therapy caused few side effects and was generally well tolerated by patients. The most common side effect reported during clinical trials was pain or discomfort at or near the treatment site. Please visit NeuroStar TMS to learn more.

Major Insurers Cover TMS Treatment, Including

bluecross unitedhealth cigna aetna
bluecross
unitedhealth
cigna
aetna

 Get Your Free Consultation

TMS logo

The TMS Center of the Hudson Valley is the first established TMS treatment center in Poughkeepsie, New York and the Greater Hudson Valley. Our mission is to provide personalized and effective TMS treatments for our patients.

Contact Us

370 Violet Ave Suite 204, Poughkeepsie, NY 12601